Interaction Checker

Sorafénib : interactions médicamenteuses

Sorafénib (Nexavar) présente 210 interactions documentées dans les notices FDA et les fiches d'information que nous indexons : 38 de niveau majeur, 172 de niveau modéré, 0 de niveau mineur et 0 cas où une notice ne signale aucune interaction significative. Chaque entrée ci-dessous cite la phrase sur laquelle elle repose. Cette page consacrée à un médicament est un point de départ, pas un verdict sur votre situation.

Interactions d'après la notice

Interactions majeures (38)

  • Aprépitantinhibiteur du CYP3A4Majeure

    • Strong CYP3A Inducers: Avoid strong CYP3A4 inducers. (notice Sorafénib, Interactions médicamenteuses)

  • Armodafinilstimulant du SNCMajeure

    • Strong CYP3A Inducers: Avoid strong CYP3A4 inducers. (notice Sorafénib, Interactions médicamenteuses)

  • AxitinibMajeure

    Fatal cerebrovascular accident was reported in 1/359 patients (<1%) receiving INLYTA and none of the patients receiving sorafenib [see Adverse Reactions (6.1) ] . (notice Axitinib, Mises en garde et précautions)

  • Bosentaninducteur du CYP3A4Majeure

    • Strong CYP3A Inducers: Avoid strong CYP3A4 inducers. (notice Sorafénib, Interactions médicamenteuses)

  • CarbamazépineanticonvulsivantMajeure

    • Strong CYP3A Inducers: Avoid strong CYP3A4 inducers. (notice Sorafénib, Interactions médicamenteuses)

  • CarboplatineMajeure

    • NEXAVAR in combination with carboplatin and paclitaxel is contraindicated in patients with squamous cell lung cancer [see Warnings and Precautions ( 5.8 )] . (notice Sorafénib, Contre-indications)

  • CénobamateanticonvulsivantMajeure

    • Strong CYP3A Inducers: Avoid strong CYP3A4 inducers. (notice Sorafénib, Interactions médicamenteuses)

  • CisplatineMajeure

    NEXAVAR in combination with gemcitabine/cisplatin is not recommended in patients with squamous cell lung cancer. (notice Sorafénib, Mises en garde et précautions)

  • ClobazambenzodiazépineMajeure

    • Strong CYP3A Inducers: Avoid strong CYP3A4 inducers. (notice Sorafénib, Interactions médicamenteuses)

  • Déférasiroxsupplément de ferMajeure

    • Strong CYP3A Inducers: Avoid strong CYP3A4 inducers. (notice Sorafénib, Interactions médicamenteuses)

  • DexaméthasonecorticoïdeMajeure

    • Strong CYP3A Inducers: Avoid strong CYP3A4 inducers. (notice Sorafénib, Interactions médicamenteuses)

  • ÉfavirenzantirétroviralMajeure

    • Strong CYP3A Inducers: Avoid strong CYP3A4 inducers. (notice Sorafénib, Interactions médicamenteuses)

  • Éfavirenz, lamivudine et ténofovirantirétroviralMajeure

    • Strong CYP3A Inducers: Avoid strong CYP3A4 inducers. (notice Sorafénib, Interactions médicamenteuses)

  • EslicarbazépineanticonvulsivantMajeure

    • Strong CYP3A Inducers: Avoid strong CYP3A4 inducers. (notice Sorafénib, Interactions médicamenteuses)

  • ÉtravirineantirétroviralMajeure

    • Strong CYP3A Inducers: Avoid strong CYP3A4 inducers. (notice Sorafénib, Interactions médicamenteuses)

  • FosphénytoïneanticonvulsivantMajeure

    • Strong CYP3A Inducers: Avoid strong CYP3A4 inducers. (notice Sorafénib, Interactions médicamenteuses)

  • GemcitabineantimétaboliteMajeure

    NEXAVAR in combination with gemcitabine/cisplatin is not recommended in patients with squamous cell lung cancer. (notice Sorafénib, Mises en garde et précautions)

  • GriséofulvineantifongiqueMajeure

    • Strong CYP3A Inducers: Avoid strong CYP3A4 inducers. (notice Sorafénib, Interactions médicamenteuses)

  • Lopinavir et ritonavirantirétroviralMajeure

    • Strong CYP3A Inducers: Avoid strong CYP3A4 inducers. (notice Sorafénib, Interactions médicamenteuses)

  • Lorlatinibinducteur du CYP3A4Majeure

    • Strong CYP3A Inducers: Avoid strong CYP3A4 inducers. (notice Sorafénib, Interactions médicamenteuses)

  • Mitapivatinducteur du CYP3A4Majeure

    • Strong CYP3A Inducers: Avoid strong CYP3A4 inducers. (notice Sorafénib, Interactions médicamenteuses)

  • Mitotaneinducteur du CYP3A4Majeure

    • Strong CYP3A Inducers: Avoid strong CYP3A4 inducers. (notice Sorafénib, Interactions médicamenteuses)

  • Modafinilstimulant du SNCMajeure

    • Strong CYP3A Inducers: Avoid strong CYP3A4 inducers. (notice Sorafénib, Interactions médicamenteuses)

  • Nafcillineantibiotique de la famille des pénicillinesMajeure

    • Strong CYP3A Inducers: Avoid strong CYP3A4 inducers. (notice Sorafénib, Interactions médicamenteuses)

  • NéomycineaminosideMajeure

    Avoid concomitant use of NEXAVAR with neomycin. (notice Sorafénib, Interactions médicamenteuses)

  • NévirapineantirétroviralMajeure

    • Strong CYP3A Inducers: Avoid strong CYP3A4 inducers. (notice Sorafénib, Interactions médicamenteuses)

  • OxcarbazépineanticonvulsivantMajeure

    • Strong CYP3A Inducers: Avoid strong CYP3A4 inducers. (notice Sorafénib, Interactions médicamenteuses)

  • PaclitaxelMajeure

    • NEXAVAR in combination with carboplatin and paclitaxel is contraindicated in patients with squamous cell lung cancer [see Warnings and Precautions ( 5.8 )] . (notice Sorafénib, Contre-indications)

  • PhénobarbitalbarbituriqueMajeure

    • Strong CYP3A Inducers: Avoid strong CYP3A4 inducers. (notice Sorafénib, Interactions médicamenteuses)

  • Phentermine et topiramatestimulant du SNCMajeure

    • Strong CYP3A Inducers: Avoid strong CYP3A4 inducers. (notice Sorafénib, Interactions médicamenteuses)

  • PhénytoïneanticonvulsivantMajeure

    • Strong CYP3A Inducers: Avoid strong CYP3A4 inducers. (notice Sorafénib, Interactions médicamenteuses)

  • PrimidoneanticonvulsivantMajeure

    • Strong CYP3A Inducers: Avoid strong CYP3A4 inducers. (notice Sorafénib, Interactions médicamenteuses)

  • RifabutineantibiotiqueMajeure

    • Strong CYP3A Inducers: Avoid strong CYP3A4 inducers. (notice Sorafénib, Interactions médicamenteuses)

  • RifampicineantibiotiqueMajeure

    • Strong CYP3A Inducers: Avoid strong CYP3A4 inducers. (notice Sorafénib, Interactions médicamenteuses)

  • RifapentineantibiotiqueMajeure

    • Strong CYP3A Inducers: Avoid strong CYP3A4 inducers. (notice Sorafénib, Interactions médicamenteuses)

  • RitonavirantirétroviralMajeure

    • Strong CYP3A Inducers: Avoid strong CYP3A4 inducers. (notice Sorafénib, Interactions médicamenteuses)

  • Suzétrigineinducteur du CYP3A4Majeure

    • Strong CYP3A Inducers: Avoid strong CYP3A4 inducers. (notice Sorafénib, Interactions médicamenteuses)

  • TopiramateanticonvulsivantMajeure

    • Strong CYP3A Inducers: Avoid strong CYP3A4 inducers. (notice Sorafénib, Interactions médicamenteuses)

Interactions modérées (172)

  • AcébutololbêtabloquantModérée

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (notice Sorafénib, Mises en garde et précautions)

  • Acide étacryniquediurétique de l'anseModérée

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (notice Sorafénib, Mises en garde et précautions)

  • AdénosineantiarythmiqueModérée

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (notice Sorafénib, Mises en garde et précautions)

  • AlfuzosinealphabloquantModérée

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (notice Sorafénib, Mises en garde et précautions)

  • AliskirèneantihypertenseurModérée

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (notice Sorafénib, Mises en garde et précautions)

  • Amiloridediurétique épargneur de potassiumModérée

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (notice Sorafénib, Mises en garde et précautions)

  • AmiodaroneantiarythmiqueModérée

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (notice Sorafénib, Mises en garde et précautions)

  • Amitriptylineantidépresseur tricycliqueModérée

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (notice Sorafénib, Mises en garde et précautions)

  • Amlodipineinhibiteur calcique dihydropyridiniqueModérée

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (notice Sorafénib, Mises en garde et précautions)

  • Amlodipine et atorvastatineinhibiteur calcique dihydropyridiniqueModérée

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (notice Sorafénib, Mises en garde et précautions)

  • Amlodipine et bénazéprilinhibiteur calcique dihydropyridiniqueModérée

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (notice Sorafénib, Mises en garde et précautions)

  • Amlodipine et olmésartaninhibiteur calcique dihydropyridiniqueModérée

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (notice Sorafénib, Mises en garde et précautions)

  • Amlodipine et valsartaninhibiteur calcique dihydropyridiniqueModérée

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (notice Sorafénib, Mises en garde et précautions)

  • Anagrélidemédicament allongeant l'intervalle QTModérée

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (notice Sorafénib, Mises en garde et précautions)

  • AsénapineantipsychotiqueModérée

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (notice Sorafénib, Mises en garde et précautions)

  • AténololbêtabloquantModérée

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (notice Sorafénib, Mises en garde et précautions)

  • Aténolol et chlortalidonebêtabloquantModérée

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (notice Sorafénib, Mises en garde et précautions)

  • Azilsartanantagoniste des récepteurs de l'angiotensine II (ARA II)Modérée

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (notice Sorafénib, Mises en garde et précautions)

  • Azithromycineantibiotique macrolideModérée

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (notice Sorafénib, Mises en garde et précautions)

  • Bénazéprilinhibiteur de l'enzyme de conversion (IEC)Modérée

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (notice Sorafénib, Mises en garde et précautions)

  • Bénazépril et hydrochlorothiazideinhibiteur de l'enzyme de conversion (IEC)Modérée

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (notice Sorafénib, Mises en garde et précautions)

  • BétaxololbêtabloquantModérée

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (notice Sorafénib, Mises en garde et précautions)

  • BisoprololbêtabloquantModérée

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (notice Sorafénib, Mises en garde et précautions)

  • Bisoprolol et hydrochlorothiazidebêtabloquantModérée

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (notice Sorafénib, Mises en garde et précautions)

  • Candésartanantagoniste des récepteurs de l'angiotensine II (ARA II)Modérée

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (notice Sorafénib, Mises en garde et précautions)

  • Candésartan et hydrochlorothiazideantagoniste des récepteurs de l'angiotensine II (ARA II)Modérée

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (notice Sorafénib, Mises en garde et précautions)

  • Captoprilinhibiteur de l'enzyme de conversion (IEC)Modérée

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (notice Sorafénib, Mises en garde et précautions)

  • CarvédilolbêtabloquantModérée

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (notice Sorafénib, Mises en garde et précautions)

  • ChloroquineantipaludiqueModérée

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (notice Sorafénib, Mises en garde et précautions)

  • Chlorothiazidediurétique thiazidiqueModérée

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (notice Sorafénib, Mises en garde et précautions)

  • ChlorpromazineantipsychotiqueModérée

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (notice Sorafénib, Mises en garde et précautions)

  • Chlortalidonediurétique thiazidiqueModérée

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (notice Sorafénib, Mises en garde et précautions)

  • CiprofloxacinefluoroquinoloneModérée

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (notice Sorafénib, Mises en garde et précautions)

  • CitalopramISRSModérée

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (notice Sorafénib, Mises en garde et précautions)

  • Clarithromycineantibiotique macrolideModérée

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (notice Sorafénib, Mises en garde et précautions)

  • Clonidineagoniste alpha-adrénergiqueModérée

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (notice Sorafénib, Mises en garde et précautions)

  • ClozapineantipsychotiqueModérée

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (notice Sorafénib, Mises en garde et précautions)

  • Deutétrabénazineinhibiteur de VMAT2Modérée

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (notice Sorafénib, Mises en garde et précautions)

  • Dextrométhorphane et quinidinemédicament sérotoninergiqueModérée

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (notice Sorafénib, Mises en garde et précautions)

  • Digoxineglycoside digitaliqueModérée

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (notice Sorafénib, Mises en garde et précautions)

  • Diltiazeminhibiteur calciqueModérée

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (notice Sorafénib, Mises en garde et précautions)

  • Dinitrate d'isosorbide et hydralazinedérivé nitréModérée

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (notice Sorafénib, Mises en garde et précautions)

  • DisopyramideantiarythmiqueModérée

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (notice Sorafénib, Mises en garde et précautions)

  • DofétilideantiarythmiqueModérée

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (notice Sorafénib, Mises en garde et précautions)

  • DoxazosinealphabloquantModérée

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (notice Sorafénib, Mises en garde et précautions)

  • DronédaroneantiarythmiqueModérée

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (notice Sorafénib, Mises en garde et précautions)

  • Dropéridolantagoniste de la dopamineModérée

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (notice Sorafénib, Mises en garde et précautions)

  • Énalaprilinhibiteur de l'enzyme de conversion (IEC)Modérée

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (notice Sorafénib, Mises en garde et précautions)

  • Énalapril et hydrochlorothiazideinhibiteur de l'enzyme de conversion (IEC)Modérée

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (notice Sorafénib, Mises en garde et précautions)

  • Énalaprilateinhibiteur de l'enzyme de conversion (IEC)Modérée

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (notice Sorafénib, Mises en garde et précautions)

  • Éplérénoneantagoniste de l'aldostéroneModérée

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (notice Sorafénib, Mises en garde et précautions)

  • Érythromycineantibiotique macrolideModérée

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (notice Sorafénib, Mises en garde et précautions)

  • EscitalopramISRSModérée

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (notice Sorafénib, Mises en garde et précautions)

  • EsmololbêtabloquantModérée

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (notice Sorafénib, Mises en garde et précautions)

  • Félodipineinhibiteur calcique dihydropyridiniqueModérée

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (notice Sorafénib, Mises en garde et précautions)

  • FingolimodimmunosuppresseurModérée

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (notice Sorafénib, Mises en garde et précautions)

  • FlécaïnideantiarythmiqueModérée

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (notice Sorafénib, Mises en garde et précautions)

  • Fluconazoleantifongique azoléModérée

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (notice Sorafénib, Mises en garde et précautions)

  • FluoxétineISRSModérée

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (notice Sorafénib, Mises en garde et précautions)

  • Fosinoprilinhibiteur de l'enzyme de conversion (IEC)Modérée

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (notice Sorafénib, Mises en garde et précautions)

  • Fosinopril et hydrochlorothiazideinhibiteur de l'enzyme de conversion (IEC)Modérée

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (notice Sorafénib, Mises en garde et précautions)

  • Furosémidediurétique de l'anseModérée

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (notice Sorafénib, Mises en garde et précautions)

  • Granisétronmédicament allongeant l'intervalle QTModérée

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (notice Sorafénib, Mises en garde et précautions)

  • Guanfacineagoniste alpha-adrénergiqueModérée

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (notice Sorafénib, Mises en garde et précautions)

  • HalopéridolantipsychotiqueModérée

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (notice Sorafénib, Mises en garde et précautions)

  • HydralazinevasodilatateurModérée

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (notice Sorafénib, Mises en garde et précautions)

  • Hydrochlorothiazidediurétique thiazidiqueModérée

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (notice Sorafénib, Mises en garde et précautions)

  • Hydroxychloroquinemédicament allongeant l'intervalle QTModérée

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (notice Sorafénib, Mises en garde et précautions)

  • HydroxyzineantihistaminiqueModérée

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (notice Sorafénib, Mises en garde et précautions)

  • IbutilideantiarythmiqueModérée

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (notice Sorafénib, Mises en garde et précautions)

  • IlopéridoneantipsychotiqueModérée

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (notice Sorafénib, Mises en garde et précautions)

  • Indapamidediurétique thiazidiqueModérée

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (notice Sorafénib, Mises en garde et précautions)

  • Irbésartanantagoniste des récepteurs de l'angiotensine II (ARA II)Modérée

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (notice Sorafénib, Mises en garde et précautions)

  • Irbésartan et hydrochlorothiazideantagoniste des récepteurs de l'angiotensine II (ARA II)Modérée

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (notice Sorafénib, Mises en garde et précautions)

  • Isradipineinhibiteur calcique dihydropyridiniqueModérée

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (notice Sorafénib, Mises en garde et précautions)

  • Kétoconazoleantifongique azoléModérée

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (notice Sorafénib, Mises en garde et précautions)

  • LabétalolbêtabloquantModérée

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (notice Sorafénib, Mises en garde et précautions)

  • LévofloxacinefluoroquinoloneModérée

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (notice Sorafénib, Mises en garde et précautions)

  • Lévothyroxinehormone thyroïdienneModérée

    • Impairment of Thyroid Stimulating Hormone Suppression (TSH) in DTC : Monitor TSH monthly and adjust thyroid replacement therapy in patients with thyroid cancer. (notice Sorafénib, Mises en garde et précautions)

  • Lévothyroxine et liothyroninehormone thyroïdienneModérée

    • Impairment of Thyroid Stimulating Hormone Suppression (TSH) in DTC : Monitor TSH monthly and adjust thyroid replacement therapy in patients with thyroid cancer. (notice Sorafénib, Mises en garde et précautions)

  • Lidocaïneanesthésique localModérée

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (notice Sorafénib, Mises en garde et précautions)

  • Lidocaïne et prilocaïneanesthésique localModérée

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (notice Sorafénib, Mises en garde et précautions)

  • Liothyroninehormone thyroïdienneModérée

    • Impairment of Thyroid Stimulating Hormone Suppression (TSH) in DTC : Monitor TSH monthly and adjust thyroid replacement therapy in patients with thyroid cancer. (notice Sorafénib, Mises en garde et précautions)

  • Lisinoprilinhibiteur de l'enzyme de conversion (IEC)Modérée

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (notice Sorafénib, Mises en garde et précautions)

  • Lisinopril et hydrochlorothiazideinhibiteur de l'enzyme de conversion (IEC)Modérée

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (notice Sorafénib, Mises en garde et précautions)

  • Lofexidineagoniste alpha-adrénergiqueModérée

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (notice Sorafénib, Mises en garde et précautions)

  • Lopéramidemédicament allongeant l'intervalle QTModérée

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (notice Sorafénib, Mises en garde et précautions)

  • Losartanantagoniste des récepteurs de l'angiotensine II (ARA II)Modérée

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (notice Sorafénib, Mises en garde et précautions)

  • Losartan et hydrochlorothiazideantagoniste des récepteurs de l'angiotensine II (ARA II)Modérée

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (notice Sorafénib, Mises en garde et précautions)

  • MécamylamineantihypertenseurModérée

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (notice Sorafénib, Mises en garde et précautions)

  • MéthadoneopioïdeModérée

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (notice Sorafénib, Mises en garde et précautions)

  • MéthyldopaantihypertenseurModérée

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (notice Sorafénib, Mises en garde et précautions)

  • Métolazonediurétique thiazidiqueModérée

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (notice Sorafénib, Mises en garde et précautions)

  • MétoprololbêtabloquantModérée

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (notice Sorafénib, Mises en garde et précautions)

  • Métoprolol et hydrochlorothiazidebêtabloquantModérée

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (notice Sorafénib, Mises en garde et précautions)

  • MexilétineantiarythmiqueModérée

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (notice Sorafénib, Mises en garde et précautions)

  • MinoxidilvasodilatateurModérée

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (notice Sorafénib, Mises en garde et précautions)

  • Moexiprilinhibiteur de l'enzyme de conversion (IEC)Modérée

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (notice Sorafénib, Mises en garde et précautions)

  • MoxifloxacinefluoroquinoloneModérée

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (notice Sorafénib, Mises en garde et précautions)

  • NadololbêtabloquantModérée

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (notice Sorafénib, Mises en garde et précautions)

  • NébivololbêtabloquantModérée

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (notice Sorafénib, Mises en garde et précautions)

  • Nicardipineinhibiteur calcique dihydropyridiniqueModérée

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (notice Sorafénib, Mises en garde et précautions)

  • Nifédipineinhibiteur calcique dihydropyridiniqueModérée

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (notice Sorafénib, Mises en garde et précautions)

  • Nilotinibmédicament allongeant l'intervalle QTModérée

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (notice Sorafénib, Mises en garde et précautions)

  • Nisoldipineinhibiteur calcique dihydropyridiniqueModérée

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (notice Sorafénib, Mises en garde et précautions)

  • Nitroprussiate de sodiumvasodilatateurModérée

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (notice Sorafénib, Mises en garde et précautions)

  • OfloxacinefluoroquinoloneModérée

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (notice Sorafénib, Mises en garde et précautions)

  • Olanzapine et fluoxétineantipsychotiqueModérée

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (notice Sorafénib, Mises en garde et précautions)

  • Olmésartanantagoniste des récepteurs de l'angiotensine II (ARA II)Modérée

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (notice Sorafénib, Mises en garde et précautions)

  • Olmésartan et hydrochlorothiazideantagoniste des récepteurs de l'angiotensine II (ARA II)Modérée

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (notice Sorafénib, Mises en garde et précautions)

  • Olmésartan, amlodipine et hydrochlorothiazideantagoniste des récepteurs de l'angiotensine II (ARA II)Modérée

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (notice Sorafénib, Mises en garde et précautions)

  • Ondansétronmédicament allongeant l'intervalle QTModérée

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (notice Sorafénib, Mises en garde et précautions)

  • PalipéridoneantipsychotiqueModérée

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (notice Sorafénib, Mises en garde et précautions)

  • Pentamidinemédicament allongeant l'intervalle QTModérée

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (notice Sorafénib, Mises en garde et précautions)

  • Périndoprilinhibiteur de l'enzyme de conversion (IEC)Modérée

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (notice Sorafénib, Mises en garde et précautions)

  • PhénoxybenzaminealphabloquantModérée

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (notice Sorafénib, Mises en garde et précautions)

  • PimavansérineantipsychotiqueModérée

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (notice Sorafénib, Mises en garde et précautions)

  • PimozideantipsychotiqueModérée

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (notice Sorafénib, Mises en garde et précautions)

  • PindololbêtabloquantModérée

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (notice Sorafénib, Mises en garde et précautions)

  • Pitolisantmédicament allongeant l'intervalle QTModérée

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (notice Sorafénib, Mises en garde et précautions)

  • Posaconazoleantifongique azoléModérée

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (notice Sorafénib, Mises en garde et précautions)

  • PrazosinealphabloquantModérée

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (notice Sorafénib, Mises en garde et précautions)

  • ProcaïnamideantiarythmiqueModérée

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (notice Sorafénib, Mises en garde et précautions)

  • ProméthazineantihistaminiqueModérée

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (notice Sorafénib, Mises en garde et précautions)

  • Prométhazine et codéineopioïdeModérée

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (notice Sorafénib, Mises en garde et précautions)

  • Prométhazine et dextrométhorphaneantihistaminiqueModérée

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (notice Sorafénib, Mises en garde et précautions)

  • PropafénoneantiarythmiqueModérée

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (notice Sorafénib, Mises en garde et précautions)

  • PropranololbêtabloquantModérée

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (notice Sorafénib, Mises en garde et précautions)

  • PropylthiouracileantithyroïdienModérée

    • Impairment of Thyroid Stimulating Hormone Suppression (TSH) in DTC : Monitor TSH monthly and adjust thyroid replacement therapy in patients with thyroid cancer. (notice Sorafénib, Mises en garde et précautions)

  • QuétiapineantipsychotiqueModérée

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (notice Sorafénib, Mises en garde et précautions)

  • Quinaprilinhibiteur de l'enzyme de conversion (IEC)Modérée

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (notice Sorafénib, Mises en garde et précautions)

  • Quinapril et hydrochlorothiazideinhibiteur de l'enzyme de conversion (IEC)Modérée

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (notice Sorafénib, Mises en garde et précautions)

  • QuinidineantiarythmiqueModérée

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (notice Sorafénib, Mises en garde et précautions)

  • QuinineantipaludiqueModérée

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (notice Sorafénib, Mises en garde et précautions)

  • Ramiprilinhibiteur de l'enzyme de conversion (IEC)Modérée

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (notice Sorafénib, Mises en garde et précautions)

  • Ranolazinemédicament allongeant l'intervalle QTModérée

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (notice Sorafénib, Mises en garde et précautions)

  • RispéridoneantipsychotiqueModérée

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (notice Sorafénib, Mises en garde et précautions)

  • Sacubitril et valsartanantagoniste des récepteurs de l'angiotensine II (ARA II)Modérée

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (notice Sorafénib, Mises en garde et précautions)

  • SolifénacineanticholinergiqueModérée

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (notice Sorafénib, Mises en garde et précautions)

  • SotalolbêtabloquantModérée

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (notice Sorafénib, Mises en garde et précautions)

  • Spironolactoneantagoniste de l'aldostéroneModérée

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (notice Sorafénib, Mises en garde et précautions)

  • Spironolactone et hydrochlorothiazideantagoniste de l'aldostéroneModérée

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (notice Sorafénib, Mises en garde et précautions)

  • TacrolimusimmunosuppresseurModérée

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (notice Sorafénib, Mises en garde et précautions)

  • Tamoxifènemodulateur sélectif des récepteurs aux estrogènesModérée

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (notice Sorafénib, Mises en garde et précautions)

  • Telmisartanantagoniste des récepteurs de l'angiotensine II (ARA II)Modérée

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (notice Sorafénib, Mises en garde et précautions)

  • Telmisartan et amlodipineantagoniste des récepteurs de l'angiotensine II (ARA II)Modérée

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (notice Sorafénib, Mises en garde et précautions)

  • Telmisartan et hydrochlorothiazideantagoniste des récepteurs de l'angiotensine II (ARA II)Modérée

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (notice Sorafénib, Mises en garde et précautions)

  • TérazosinealphabloquantModérée

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (notice Sorafénib, Mises en garde et précautions)

  • Tériparatidehormone thyroïdienneModérée

    • Impairment of Thyroid Stimulating Hormone Suppression (TSH) in DTC : Monitor TSH monthly and adjust thyroid replacement therapy in patients with thyroid cancer. (notice Sorafénib, Mises en garde et précautions)

  • Tétrabénazineinhibiteur de VMAT2Modérée

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (notice Sorafénib, Mises en garde et précautions)

  • ThiamazoleantithyroïdienModérée

    • Impairment of Thyroid Stimulating Hormone Suppression (TSH) in DTC : Monitor TSH monthly and adjust thyroid replacement therapy in patients with thyroid cancer. (notice Sorafénib, Mises en garde et précautions)

  • ThioridazineantipsychotiqueModérée

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (notice Sorafénib, Mises en garde et précautions)

  • TizanidinemyorelaxantModérée

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (notice Sorafénib, Mises en garde et précautions)

  • ToltérodineanticholinergiqueModérée

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (notice Sorafénib, Mises en garde et précautions)

  • Torasémidediurétique de l'anseModérée

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (notice Sorafénib, Mises en garde et précautions)

  • Torémifènemodulateur sélectif des récepteurs aux estrogènesModérée

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (notice Sorafénib, Mises en garde et précautions)

  • TramadolopioïdeModérée

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (notice Sorafénib, Mises en garde et précautions)

  • Tramadol et paracétamolopioïdeModérée

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (notice Sorafénib, Mises en garde et précautions)

  • Trandolaprilinhibiteur de l'enzyme de conversion (IEC)Modérée

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (notice Sorafénib, Mises en garde et précautions)

  • TrazodoneantidépresseurModérée

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (notice Sorafénib, Mises en garde et précautions)

  • Triamtérènediurétique épargneur de potassiumModérée

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (notice Sorafénib, Mises en garde et précautions)

  • Triamtérène et hydrochlorothiazidediurétique épargneur de potassiumModérée

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (notice Sorafénib, Mises en garde et précautions)

  • Trioxyde d'arsenicmédicament allongeant l'intervalle QTModérée

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (notice Sorafénib, Mises en garde et précautions)

  • Valbénazineinhibiteur de VMAT2Modérée

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (notice Sorafénib, Mises en garde et précautions)

  • Valsartanantagoniste des récepteurs de l'angiotensine II (ARA II)Modérée

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (notice Sorafénib, Mises en garde et précautions)

  • Valsartan et hydrochlorothiazideantagoniste des récepteurs de l'angiotensine II (ARA II)Modérée

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (notice Sorafénib, Mises en garde et précautions)

  • Vardénafilinhibiteur de la PDE5Modérée

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (notice Sorafénib, Mises en garde et précautions)

  • VenlafaxineIRSNaModérée

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (notice Sorafénib, Mises en garde et précautions)

  • Vérapamilinhibiteur calciqueModérée

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (notice Sorafénib, Mises en garde et précautions)

  • Voriconazoleantifongique azoléModérée

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (notice Sorafénib, Mises en garde et précautions)

  • WarfarineanticoagulantModérée

    Increased Risk of Bleeding with Concomitant Use of Warfarin Infrequent bleeding or elevations in the International Normalized Ratio (INR) have been reported in some patients taking warfarin while on NEXAVAR. (notice Sorafénib, Mises en garde et précautions)

  • ZiprasidoneantipsychotiqueModérée

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (notice Sorafénib, Mises en garde et précautions)

Vérifiez Sorafénib avec tout ce que vous prenez. Ajoutez votre liste complète ; toutes les paires sont vérifiées en une fois.

Ouvrir dans le vérificateur

Ceci n'est pas un avis médical. Le niveau de gravité reflète la formulation de la notice, pas votre situation. Une alerte « majeure » peut être courante sous surveillance et une alerte « mineure » peut compter à forte dose. Demandez conseil à un pharmacien.